Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Evaluation of the MammaTyperVR as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes (2018) Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al. Conference contribution Validation of the MammaTyper (R) pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC) (2018) Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al. Conference contribution Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study (2018) Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study (2018) Fasching P, Decker T, Guderian G, Heim J, Jackisch C, Lueck HJ, Lueftner D, et al. Conference contribution Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3 (2018) Fasching P, Esteva FJ, Pivot X, Nusch A, Beck JT, Chan A, Pieris-Gunatilaka A, et al. Conference contribution A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients (2018) Häberle L, Erber R, Gaß P, Hein A, Jud S, Langemann H, Rauh C, et al. Conference contribution Tumor-infiltrating CD8-positive T-lymphocytes in tubo-ovarian high-grade serous cancer are associated with multiple germline variants in 22q12.1 in a genome-wide association analysis (2018) Natanzon Y, Kobel M, Winham SJ, Armasu SM, Mccauley BM, Vierkant RA, Cunningham JM, et al. Conference contribution Joint genome-wide association study of endometrial cancer and ovarian cancer identifies a novel genetic risk region at 14q23.3 (2018) O'Mara TA, Glubb DM, Buchanan DD, Lambrechts D, Hall P, Tham E, Trovik J, et al. Conference contribution Mutational diversity and therapy response in breast cancer-a sequencing analysis in the neoadjuvant GeparSepto trial (2018) Loibl S, Treue D, Budczies J, Weber K, Stenzinger A, Schmitt WD, Weichert W, et al. Conference contribution Evidence for a shared genetic basis between breast cancer and mammographic density phenotypes (2018) Chen H, Douglas J, Gordon W, Thompson D, Couch F, Fasching P, Hall P, et al. Conference contribution